Haemopoiesis & Red Cell Life Cycle

Haemopoiesis is the orderly production of all blood cellular elements from a common pluripotent stem cell. For NEET PG, the high-yield threads are the shifting sites of blood formation across life, the morphological stages of erythropoiesis, erythropoietin (EPO) regulation by renal hypoxia sensors, the 120-day RBC lifespan, normal red cell indices, and how senescent cells are dismantled. Master these and the entire anaemia-classification framework falls into place.

Definition & overview

Haemopoiesis (haematopoiesis) begins with the pluripotent haematopoietic stem cell (PHSC / HSC), which is CD34⁺ and capable of both self-renewal and differentiation. The HSC gives rise to two committed progenitors:

• Common myeloid progenitor (CMP) → erythrocytes, megakaryocytes/platelets, granulocytes (neutrophils, eosinophils, basophils), monocytes, mast cells.
• Common lymphoid progenitor (CLP) → T lymphocytes, B lymphocytes, NK cells.

Progenitors are functionally defined as colony-forming units (CFU). The earliest erythroid-committed cell is BFU-E (burst-forming unit–erythroid), which matures into CFU-E (colony-forming unit–erythroid), the cell most sensitive to erythropoietin.

High-yield: The pluripotent stem cell and most progenitors express CD34. CFU-E (not BFU-E) carries the highest density of erythropoietin receptors and is the principal EPO-responsive cell.

Sites of haemopoiesis — the developmental shift

The location of blood formation migrates predictably during gestation and after birth. This sequence is a perennial one-liner MCQ.

Yolk sac (mesoblastic, ~3rd week) → Liver (hepatic, dominant 2nd trimester) → Spleen (also 2nd trimester) → Bone marrow (myeloid, from ~5th–7th month, dominant from birth)

Phase	Timing	Primary site(s)	Notes
Mesoblastic	Weeks 2–8 (3rd week onset)	Yolk sac (blood islands)	Produces primitive nucleated RBCs; chiefly Hb Gower 1, Gower 2, Portland
Hepatic	6 weeks – birth (peak 2nd trimester)	Liver (chief fetal site), spleen, lymph nodes	Liver is the main site of fetal haemopoiesis; HbF predominates
Myeloid (medullary)	From ~5th month, lifelong	Bone marrow	Becomes sole normal site after birth

After birth, all marrow is red (active) at first. By adulthood, active red marrow is confined to the axial skeleton — vertebrae, sternum, ribs, skull, pelvis, and proximal epiphyses of femur and humerus. The remaining marrow becomes fatty yellow marrow, which can revert to red marrow under chronic haemolytic stress.

High-yield: The liver is the principal site of haemopoiesis during fetal life. The yolk sac is the first site. Spleen participates in the fetus but is NOT a normal postnatal site — splenic/hepatic haemopoiesis after birth = extramedullary haemopoiesis (seen in thalassaemia major, myelofibrosis, severe chronic haemolysis).

Erythropoiesis — stages from proerythroblast to RBC

Erythroid maturation proceeds through recognisable stages. The unifying theme: nucleus shrinks then is extruded, cytoplasm becomes progressively more eosinophilic (haemoglobinised), and overall cell size decreases.

Proerythroblast → Basophilic erythroblast → Polychromatophilic erythroblast → Orthochromatic erythroblast (normoblast) → Reticulocyte → Mature erythrocyte

Stage	Size	Nucleus	Cytoplasm	Key event
Proerythroblast	Largest (~14–19 µm)	Large, open chromatin, nucleoli	Deep basophilic	First recognisable; CFU-E derived
Basophilic erythroblast	Smaller	Condensing, no nucleoli	Strongly basophilic (ribosome-rich)	Maximal Hb synthesis machinery
Polychromatophilic erythroblast	Smaller	More condensed	Grey-blue (Hb + ribosomes)	Last stage capable of mitosis
Orthochromatic erythroblast (normoblast)	~8–10 µm	Small, pyknotic, eccentric	Pink (eosinophilic)	Nucleus extruded here
Reticulocyte	Slightly larger than RBC	None	Residual RNA (reticulum on supravital stain)	Enters blood; matures in 1–2 days
Erythrocyte	~7.2–7.5 µm	None	Pink, biconcave	No nucleus, no organelles

Key points often tested:

• The orthochromatic normoblast extrudes its nucleus to become a reticulocyte. Mammalian mature RBCs are anucleate and lack mitochondria and ribosomes, so they rely on anaerobic glycolysis for ATP.
• Reticulocytes spend ~2–3 days in marrow and ~1 day in circulation before maturing. Residual RNA is stained by new methylene blue / brilliant cresyl blue (supravital stains).
• Total maturation from proerythroblast to reticulocyte takes ~7 days.
• Howell–Jolly bodies (nuclear DNA remnants) are normally removed by the spleen → their presence suggests hyposplenism/asplenia.

High-yield: The polychromatophilic erythroblast is the last erythroid stage capable of division. Reticulocyte count is the single best bedside index of marrow erythropoietic activity — corrected reticulocyte count or reticulocyte production index (RPI) distinguishes hyperproliferative (haemolysis/blood loss) from hypoproliferative anaemias.

Erythropoietin — the master regulator

Erythropoietin (EPO) is a glycoprotein hormone and the principal regulator of red cell production.

• Site of production: ~90% from the kidney, specifically peritubular interstitial (fibroblast-like) cells of the renal cortex/outer medulla. ~10% from the liver (the main extra-renal source, dominant in the fetus).
• Stimulus: Tissue hypoxia (low O₂ delivery), e.g. anaemia, high altitude, chronic hypoxaemia, haemorrhage.
• Sensor mechanism: Hypoxia stabilises HIF-1α / HIF-2α (hypoxia-inducible factor). Under normoxia, prolyl hydroxylase (PHD) hydroxylates HIF-α, allowing VHL-mediated ubiquitination and degradation. Under hypoxia, hydroxylation fails, HIF-α accumulates, dimerises with HIF-β, and transcribes the EPO gene.
• Action: Binds EPO receptor on CFU-E and early erythroblasts → prevents apoptosis, drives proliferation and maturation → raises reticulocyte output (visible in 3–5 days).

High-yield: Renal peritubular interstitial cells sense hypoxia and secrete EPO via the HIF–PHD–VHL pathway. This explains anaemia of chronic kidney disease (low EPO) and secondary polycythaemia in chronic hypoxia, renal cell carcinoma, and high altitude. VHL mutations / PHD2 mutations → Chuvash and familial polycythaemias.

Clinical correlates of EPO:

• CKD → ↓EPO → normocytic normochromic anaemia → treated with recombinant EPO / darbepoetin or HIF-PH inhibitors (e.g. roxadustat).
• EPO doping in athletes; paraneoplastic EPO from RCC, hepatocellular carcinoma, cerebellar haemangioblastoma, uterine leiomyoma.

Substrates and vitamins required

Erythropoiesis needs raw materials, deficiency of which produces classic anaemias:

Nutrient	Role	Deficiency morphology
Iron	Haem synthesis	Microcytic hypochromic
Vitamin B12 (cobalamin)	DNA synthesis (methionine synthase)	Macrocytic megaloblastic
Folate	DNA synthesis (thymidylate)	Macrocytic megaloblastic
Vitamin B6 (pyridoxine)	ALA synthase cofactor	Sideroblastic
Erythropoietin	Proliferation/survival	Normocytic (CKD)
Protein, copper, vitamin C	Various	Variable

RBC life cycle — the 120-day journey

• Lifespan ≈ 120 days in circulation. The RBC travels ~400 km and the loss of nucleus/organelles means it cannot repair damage, so it senesces.
• Daily turnover: ~1% (0.8–1%) of RBCs are replaced each day, i.e. ~2 × 10¹¹ cells/day, balancing destruction with marrow output.
• Senescence: Ageing RBCs show ↓glycolytic enzyme activity, membrane stiffening, oxidation of band-3, and externalisation of phosphatidylserine — these act as "eat me" signals.

Destruction of senescent RBCs

Senescent RBC → recognised by splenic (and hepatic) macrophages → extravascular phagocytosis → haem split into iron + biliverdin → biliverdin → unconjugated bilirubin → liver conjugation → bile

• ~90% extravascular destruction by the reticuloendothelial / mononuclear phagocyte system — chiefly splenic macrophages ("graveyard of RBCs"), also liver (Kupffer cells) and marrow.
• Haemoglobin → globin (recycled to amino acids) + haem.
• Haem → haem oxygenase → biliverdin + CO + free iron. Biliverdin → biliverdin reductase → unconjugated (indirect) bilirubin → albumin-bound to liver → conjugated → excreted in bile → stercobilinogen/urobilinogen.
• Iron is bound to transferrin for reuse or stored as ferritin/haemosiderin.
• ~10% intravascular lysis → free Hb binds haptoglobin (cleared by liver); excess saturates haptoglobin → haemoglobinaemia, haemoglobinuria, haemosiderinuria, low haptoglobin → markers of intravascular haemolysis.

High-yield: Extravascular haemolysis → ↑unconjugated bilirubin, ↑LDH, splenomegaly, normal/mildly low haptoglobin. Intravascular haemolysis → ↓haptoglobin, haemoglobinuria, haemosiderinuria, schistocytes, markedly ↑LDH. CO produced during haem breakdown is the only endogenous source of carboxyhaemoglobin.

Normal RBC indices & values

Memorise these cut-offs — they anchor most haematology MCQs.

Parameter	Normal value
Haemoglobin (male)	13.5–17.5 g/dL
Haemoglobin (female)	12.0–15.5 g/dL
RBC count	4.5–6.5 (M), 3.8–5.8 (F) × 10¹²/L
Haematocrit (PCV)	40–54% (M), 36–48% (F)
MCV	80–100 fL
MCH	27–32 pg
MCHC	32–36 g/dL
RDW	11.5–14.5%
Reticulocyte count	0.5–2.5%
RBC diameter	7.2–7.5 µm
RBC lifespan	~120 days

• MCV = (Hct × 10) / RBC count → classifies anaemia as micro/normo/macrocytic.
• MCH = (Hb × 10) / RBC count.
• MCHC = (Hb × 100) / Hct → high MCHC is the clue for hereditary spherocytosis and autoimmune haemolytic anaemia.
• RDW measures anisocytosis; high RDW + low MCV favours iron deficiency over thalassaemia trait (normal RDW).

Anaemia classification (morphological)

This is the framework the topic underpins.

Type (by MCV)	MCV	Classic causes
Microcytic	<80 fL	Iron deficiency, thalassaemia, anaemia of chronic disease (late), sideroblastic, lead poisoning
Normocytic	80–100 fL	Acute blood loss, haemolysis, CKD, early anaemia of chronic disease, aplastic anaemia
Macrocytic	>100 fL	Megaloblastic (B12/folate); non-megaloblastic (alcohol, liver disease, hypothyroidism, reticulocytosis, myelodysplasia)

Diagnostic flow: Anaemia confirmed → check MCV → if low, iron studies / Hb electrophoresis; if normal, reticulocyte count (high = haemolysis/blood loss; low = marrow/CKD); if high, peripheral smear + B12/folate (hypersegmented neutrophils → megaloblastic).

High-yield: Hypersegmented neutrophils (≥5 lobes) = earliest smear sign of megaloblastic anaemia. Mentzer index (MCV/RBC) >13 → iron deficiency; <13 → thalassaemia trait. Microcytosis with a high RBC count points to thalassaemia trait.

Investigations & investigation of choice

• First test: Complete blood count (CBC) with indices + peripheral blood smear.
• Reticulocyte count / RPI: distinguishes hyper- vs hypoproliferative anaemia.
• Iron deficiency — investigation of choice: serum ferritin (low ferritin is the most specific single marker; ferritin is an acute-phase reactant so may be falsely normal/high in inflammation).
• Thalassaemia: Hb electrophoresis / HPLC (↑HbA₂ in β-thal trait).
• B12/folate deficiency: serum B12, serum/RBC folate; methylmalonic acid ↑ in B12 deficiency (not folate); homocysteine ↑ in both.
• Haemolysis screen: LDH, indirect bilirubin, haptoglobin, reticulocytes, DCT (Coombs) for immune cause.
• Marrow disorders: bone marrow aspiration/biopsy (gold standard for aplastic anaemia, leukaemia, myelodysplasia).

Management / drug-of-choice pointers

• Iron deficiency: oral ferrous sulphate (drug of choice); IV iron if intolerant/malabsorption; expect reticulocytosis in 5–10 days.
• B12 deficiency / pernicious anaemia: parenteral (IM) hydroxocobalamin/cyanocobalamin; never give folate alone in B12 deficiency (precipitates subacute combined degeneration).
• Folate deficiency: oral folic acid.
• Anaemia of CKD: recombinant human EPO / darbepoetin (ensure iron repletion first), or HIF-PH inhibitors.
• Aplastic anaemia: immunosuppression (ATG + ciclosporin) or allogeneic HSCT in young patients.
• Haemolytic states: treat cause; folate supplementation; splenectomy in selected (e.g. hereditary spherocytosis).

Complications & related disorders

• Extramedullary haemopoiesis → hepatosplenomegaly, "hair-on-end" skull X-ray and chipmunk facies in thalassaemia major.
• Iron overload from repeated transfusions/haemolysis → secondary haemochromatosis (treat with chelators — deferoxamine, deferasirox).
• Polycythaemia — primary (polycythaemia vera, JAK2 V617F, low EPO) vs secondary (high EPO, hypoxia/tumour).
• Pancytopenia from marrow failure or infiltration.

Key differentials worth distinguishing

Feature	Iron deficiency	β-Thalassaemia trait	Anaemia of chronic disease
MCV	Low	Low	Normal/low
RBC count	Low	High/normal	Low
RDW	High	Normal	Normal
Ferritin	Low	Normal/high	Normal/high
Serum iron / TIBC	Low / high TIBC	Normal	Low / low TIBC
HbA₂	Normal/low	Raised (>3.5%)	Normal

Recently asked / exam angle

• Site of haemopoiesis sequence and the "main fetal site = liver", "first site = yolk sac" — repeated single-best-answer favourites.
• EPO-secreting cells = renal peritubular interstitial cells; HIF–PHD–VHL pathway tied to CKD anaemia and the newer HIF-PH inhibitor drugs.
• Last dividing erythroid stage = polychromatophilic erythroblast; stage at which nucleus is extruded = orthochromatic normoblast.
• 120-day lifespan, ~1%/day turnover, and the spleen as the graveyard of RBCs.
• Markers separating intravascular vs extravascular haemolysis (haptoglobin, haemoglobinuria vs unconjugated bilirubin/splenomegaly).
• CD34 as the HSC marker; CFU-E as the most EPO-sensitive cell.
• Mentzer index and RDW to separate iron deficiency from thalassaemia trait.
• Calculation-type questions on MCV, MCH, MCHC from given Hb, Hct, RBC count.

Rapid revision

1. Haemopoiesis order: yolk sac → liver (main fetal) → spleen → bone marrow (postnatal/lifelong).
2. Adult red marrow = axial skeleton + proximal femur/humerus; rest is yellow marrow that can reactivate.
3. HSC is CD34⁺, self-renewing; CFU-E has the most EPO receptors.
4. Erythroid order: pro- → basophilic → polychromatophilic → orthochromatic → reticulocyte → RBC.
5. Polychromatophilic erythroblast = last dividing stage; orthochromatic normoblast extrudes the nucleus.
6. EPO from renal peritubular interstitial cells via HIF–PHD–VHL; ~10% hepatic (main fetal extra-renal source).
7. RBC lifespan ≈ 120 days; ~1% replaced daily; anaerobic glycolysis only (no mitochondria).
8. ~90% extravascular destruction in spleen/liver → unconjugated bilirubin; iron recycled via transferrin/ferritin.
9. Intravascular haemolysis → ↓haptoglobin, haemoglobinuria, haemosiderinuria, ↑LDH, schistocytes.
10. Normals: MCV 80–100 fL, MCH 27–32 pg, MCHC 32–36 g/dL, retics 0.5–2.5%. High MCHC → spherocytosis/AIHA.
11. Ferritin = best test for iron deficiency; Hb electrophoresis for thalassaemia (↑HbA₂); methylmalonic acid ↑ only in B12 deficiency.
12. Mentzer index >13 → iron deficiency; <13 → thalassaemia trait; hypersegmented neutrophils = megaloblastic anaemia.